This study investigated the effect on antipsychotic treatment adherence of combining quetiapine or risperidone with lithium, anticonvulsants, and/or antidepressants among bipolar individuals with predominantly manic/mixed or depressive symptoms.
Methods
Treatment episodes with quetiapine or risperidone were identified from individuals with medical claims for bipolar/manic disorder. Multiple regression analysis was used to evaluate the impact of antipsychotic combinations on treatment adherence, as measured by intensity (medication possession ratio [MPR]) and treatment duration.
Results
Among mixed/manic individuals, combination therapies were associated with lower antipsychotic MPRs than monotherapy (P < .05), with MPR decreasing with number of medications. Quetiapine showed a similar pattern among depressed individuals, whereas risperidone showed a weaker association. For both subgroups, antipsychotic combinations with anticonvulsants were associated with lower MPRs than combinations with lithium. For manic/mixed individuals, combining quetiapine with an anticonvulsant and lithium was associated with shorter treatment durations than quetiapine alone (P ≤ .05). For manic/mixed individuals receiving risperidone, treatment duration was not affected by type of combination therapy. Among depressed subgroups, treatment duration was unrelated to combination therapy.
Conclusions
Adherence to quetiapine and risperidone may be affected by whether they are prescribed alone or as combination therapy, the combination strategy, and the predominant symptomatology of the individual.
ZarateCAQuirozJA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 2003;5:217–225.
2.
KeckPE. Long-term management strategies to achieve optimal function in patients with bipolar disorder. J Clin Psychiatry. 2006, 67(suppl 9):19–24.
3.
BowdenCL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry. 2005, 66(suppl 3):12–19.
4.
GrofP.Selecting effective long-term treatment for bipolar individuals: monotherapy and combinations. J Clin Psychiatry. 2003, 64(suppl 5):53–61.
5.
NemeroffCB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005, 66(suppl 8):13–21.
6.
FryeMAKetterTALeverichGS. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9–15.
7.
WolfspergerMGreilWRosslerW. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord. 2007;99:9–17.
8.
KeckPEJr. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry. 2005, 66(suppl 3):5–11.
9.
SuppesTDennehyEBHirschfeldRM; Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870–886.
10.
HirschfeldRMABowdenLGitlinMJ, for the Work Group on Bipolar Disorder. Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd ed. Arlington, VA: American Psychiatric Association; 2002:1–82.
11.
GoodwinGM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17:149–173.
12.
YathamLNKennedySHO'DonovanC. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005, 7(suppl 3):5–69.
13.
LinDMokHYathamLN. Polytherapy in bipolar disorder. CNS Drugs. 2006;20:29–42.
14.
BowdenCLKetterTASachsGS. Focus on bipolar disorder treatment. J Clin Psychiatry. 2005;66:1598–1609.
15.
KetterTANasrallahHAFagioliniA.Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol Bull. 2006;39:120–146.
16.
KingsburySJYiDSimpsonGM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv. 2001;52:1033–1036.
17.
FinckeBGMillerDRSpiroA.The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med. 1998;13:182–185.
18.
BurtonSC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract. 2005;1:369–378.
19.
WestJCWilkJEOlfsonM. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv. 2005;56:283–291.
20.
BowdenCL. Making optimal use of combination pharmacotherapy in bipolar disorder. J Clin Psychiatry. 2004, 65(suppl 15):21–24.
21.
SvarstadBLShiremanTISweeneyJK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805–811.
22.
DolderCRLacroJPDunnLB. Antipsychotic medication adherence: is there a difference between typical and atypical agents?Am J Psychiatry. 2002;159:103–108.
23.
SajatovicMValensteinMBlowFC. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8:232–241.
24.
American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.
25.
PerlickDARosenheckRAKaczynskiR. Medication non-adherence in bipolar disorder: a patient-centered review of research findings. Clinical Approaches in Bipolar Disorder. 2004;3:56–64.
26.
SinghVBowdenCL. Concepts surrounding the diagnosis and treatment of mixed states in bipolar disorders. Clinical Approaches in Bipolar Disorder. 2005;4:35–43.
27.
PaykelES. The evolution of life events research in psychiatry. J Affect Disord. 2001;62:141–149.
28.
Centers for Disease Control and Prevention, Centers for Medicare & Medicaid Services. International Statistical Classification of Diseases, 9th revision, clinical modification (ICD-9-CM).; 2008.
29.
DasAKOlfsonMGameroffMJ. Screening for bipolar disorder in a primary care practice. JAMA. 2005;293:956–963.
30.
GianfrancescoFDRajagopalanKSajatovicM. Treatment adherence among individuals with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry. 2006;67:222–232.
31.
KeckPE. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. Postgrad Med. 2004:1–20.
32.
ColomFVietaEMartinez-AránA. Clinical factors associated with treatment noncompliance in euthymic bipolar individuals. J Clin Psychiatry. 2000;61:549–555.
33.
ValensteinMCopelandLABlowFC. Pharmacy data identify poorly adherent individuals with schizophrenia at increased risk for admission. Med Care. 2002;40:630–639.
34.
GilmerTPDolderCRLacroJP. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692–699.
35.
LindenMGodemannFGaebelW. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia individuals during 2 years. Schizophr Bull. 2001;27:585–596.
36.
NoseMBarbuiCTansellaM.How often do individuals with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003;33:1149–1160.
37.
RittmannsbergerHPachingerTKeppelmullerP. Medication adherence among psychotic individuals before admission to inpatient treatment. Psychiatr Serv. 2004;55:174–179.
38.
LacroJPDunnLBDolderCR. Prevalence of and risk factors for medication nonadherence in individuals with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.
39.
LeslieDLRosenheckRA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care. 2001;39:923–933.
40.
DiazENeuseESullivanMC. Adherence to typical and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65:354–360.
41.
BowdenCLSinghV.Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand. 2005;111:13–20.
KeckPEJr, McElroySL, StrakowskiSM, . Factors associated with pharmacologic noncompliance in individuals with mania. J Clin Psychiatry. 1996;57:292–297.
44.
CorrissDJSmithTEHullJW. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res. 1999;89:269–274.
45.
RussoPSmithMWDiraniR. Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disord. 2002;4:366–377.
46.
OwenRRFischerEPBoothBM. Medication noncompliance and substance abuse among individuals with schizophrenia. Psychiatr Serv. 1996;47:853–858.
47.
OlfsonMMechanicDHansellS. Predicting medication noncompliance after hospital discharge among individuals with schizophrenia. Psychiatr Serv. 2000;51:216–222.
48.
LambertMConusPEideP. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004;19:415–422.
49.
RobinsonDGWoernerMGAlvirJM. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209–219.
50.
BuchananA.A two-year prospective study of treatment compliance in individuals with schizophrenia. Psychol Med. 1992;22:787–797.
51.
WeidenPJKozmaCGroggA. Partial compliance and risk of rehospitalization among California Medicaid individuals with schizophrenia. Psychiatr Serv. 2004;55:886–891.
52.
ZarateCAJr. Antipsychotic drug side effect issues in bipolar manic individuals. J Clin Psychiatry. 2000, 61(suppl 8):52–61.
53.
GibsonTBOzminkowskiRJGoetzelRZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730–740.
54.
BriesacherBAGurwitzJHSoumeraiSB. Patients at risk for cost-related medication nonadherence: a review of the literature. J Gen Int Med. 2007;22:864–871.
55.
SajatovicMBauerMSKilbourneAM. Selfreported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv. 2006;57:56–62.
56.
SajatovicMValensteinMBlowF. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv. 2007;58:855–863.
57.
Al-ZakwaniISBarronJJBullanoMF. Analysis of healthcare utilization patterns and adherence in individuals receiving typical and atypical antipsychotic medications. Curr Med Res Opin. 2003;19:619–626.
